体外膜肺氧合抗凝管理进展  

Progresses in anticoagulation management of extracorporeal membrane oxygenation

作　　者：唐晓[1] 孙兵 TANG Xiao;SUN Bing(Department of Respiratory and Critical Care Medicine,Beijing Chaoyang Hospital,Capital Medical University,Beijing Institute of Respiratory Medicine,Beijing Key Laboratory of Respiratory and Pulmonary Circulation Disorders,Beijing Engineering Research Center for Diagnosis and Treatment of Respiratory and Critical Care Medicine(Beijing Chaoyang Hospital),Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院呼吸与危重症医学科,北京市呼吸疾病研究所,北京市呼吸与肺循环疾病重点实验室,北京市呼吸与危重症诊治工程技术研究中心(北京朝阳医院),北京100020

出　　处：《内科急危重症杂志》2022年第5期357-360,共4页Journal of Critical Care In Internal Medicine

基　　金：北京市医院管理中心临床技术创新项目(No:XMLX202105);北京市科学技术委员首都临床诊疗技术研究及转化应用(No:Z201100005520030)。

摘　　要：抗凝管理是体外膜肺氧合技术的重要环节,如何通过抗凝监测、抗凝目标范围的确定和抗凝药物合理选择减少出血和血栓事件发生一直是临床工作的重点。目前低强度抗凝方案仍是被普遍接受的,但抗凝监测策略及抗凝目标范围仍无统一意见。新型抗凝药物在ECMO抗凝中的应用前景也缺乏有效证据支持,均需进一步探索和研究。Anticoagulation management is an important part of extracorporeal membrane oxygenation(ECMO).Anticoagulation monitoring,reasonable anticoagulation strategy,and rational administration of anticoagulant are the focal point of the work in clinical physicians.At present,the low-dose anticoagulation strategy is still widely accepted.However,anticoagulation monitoring methods and target range are still not unified.The application prospect of novel anticoagulants is also lack of effective evidence.Many aspects about anticoagulation management during ECMO need further exploration and research.

关 键 词：体外膜肺氧合 抗凝 抗凝药物 凝血功能 

分 类 号：R563[医药卫生—呼吸系统]